Prolific Machines announced a new investment led by Atoms & Bits and Nant Capital to scale its optogenetics-enabled biomanufacturing platform.

Prolific Machines 宣布完成由 Atoms & Bits 和 Nant Capital 领投的新一轮融资，以扩大其基于光遗传学的生物制造平台。

The company also entered a strategic collaboration with NantWorks to apply its platform across biologics programs within NantWorks' health and life sciences portfolio.

该公司还与NantWorks达成战略合作，将其平台应用于NantWorks健康和生命科学组合中的生物制剂项目。

Patrick Soon-Shiong, M.D. and James Stewart have joined Prolific Machines' Board of Directors.

帕特里克·宋-雄博士和詹姆斯·斯图尔特已加入Prolific Machines的董事会。

EMERYVILLE, Calif

加利福尼亚州埃默里维尔

,

，

Oct. 14, 2026

2026年10月14日

/PRNewswire/ -- Prolific Machines, the biotechnology company advancing biologics development and manufacturing through integrated optogenetics-enabled solutions delivering breakthrough yields, superior on-target quality, and precise process control, today announced the initial closing of its $50M Series B2 financing led by Atoms & Bits, a growth-stage fund, and Nant Capital, the investment organization which is part of a portfolio of private and public companies in health and life sciences founded by Patrick Soon-Shiong, M.D.

/美通社/ -- 通过集成光遗传学赋能解决方案推动生物药开发与生产、实现突破性产量、卓越的目标质量及精准工艺控制的生物技术公司 Prolific Machines，今日宣布完成其 5,000 万美元 B2 轮融资的首次交割。本轮融资由成长阶段基金 Atoms & Bits 以及 Nant Capital 领投。Nant Capital 是由 Patrick Soon-Shiong 博士创立的医疗健康与生命科学领域私营和上市公司投资组合旗下的投资机构。

This brings the company's total funding to over $100 million..

这使得该公司的融资总额超过1亿美元。

Prolific Machines will use the new capital to scale its optogenetics platform for biomanufacturing, expanding programs with several top-20 pharma companies and multiple biotechs at its San Francisco Bay Area campus and across its CDMO network. The funding will support team growth, further technology development and scale-up across novel biologics, biosimilars and viral vector programs.

Prolific Machines 将利用新资金扩大其用于生物制造的光遗传学平台，在旧金山湾区园区及其合同研发生产组织（CDMO）网络内，与多家全球前20强制药公司及多家生物技术企业拓展合作项目。该笔资金将支持团队扩张，并推动新型生物药、生物类似药及病毒载体项目的进一步技术开发与规模化生产。

It will also fund early work toward tissue and organ fabrication..

它还将资助组织和器官制造方面的早期工作。

Prolific Machines and NantWorks also announced a strategic collaboration to apply Prolific's platform across biologic programs within NantWorks' portfolio of health and life sciences companies.

Prolific Machines 与 NantWorks 还宣布达成战略合作，将 Prolific 的平台应用于 NantWorks 旗下健康与生命科学公司组合中的生物制剂项目。

'For the last seven years the Prolific Machines team has been creating the field of Optogenetic Biomanufacturing, allowing any process inside of any cell to be controlled with light. Our goal is to provide the lowest cost and highest precision infrastructure to control biology. We have demonstrated that it works, can be scaled, and that people want it.

在过去七年里，Prolific Machines 团队开创了光遗传学生物制造领域，实现了对任何细胞内任何过程的光控。我们的目标是提供成本最低、精度最高的生物学控制基础设施。我们已经证明，该技术可行、可规模化，且受到市场青睐。

Our biggest issue now is having too much demand and this funding round changes that. We will be rapidly scaling the business over the next 12 months,' said Deniz Kent, Ph.D., CEO and Co-Founder of Prolific Machines..

“我们目前面临的最大问题是需求过于旺盛，而本轮融资将改变这一局面。我们将在未来12个月内快速扩大业务规模，”Prolific Machines 的首席执行官兼联合创始人 Deniz Kent 博士表示。

As part of the financing, James Stewart, founder of Level One Fund and Atoms & Bits, and Patrick Soon-Shiong, M.D., founder of NantWorks, have joined Prolific Machines' Board of Directors. Existing investors, including Breakthrough Energy Ventures, Mayfield, SOSV, and Fonterra's venture arm, also participated in the round..

作为融资的一部分，Level One Fund 和 Atoms & Bits 的创始人詹姆斯·斯图尔特（James Stewart），以及 NantWorks 的创始人帕特里克·宋-雄博士（Patrick Soon-Shiong, M.D.）已加入 Prolific Machines 的董事会。包括突破能源创投（Breakthrough Energy Ventures）、梅菲尔德基金（Mayfield）、SOSV 以及恒天然集团（Fonterra）旗下风险投资部门在内的现有投资者也参与了本轮融资。

'Prolific Machines is the most exciting advancement I have seen in biopharma manufacturing in decades. Deniz and his team have built the control system that has long been missing from making medicines in living cells. I look forward to NantWorks, its affiliate companies and Prolific working together on multiple fronts,' said Patrick Soon-Shiong, M.D., founder of NantWorks..

“Prolific Machines 是我数十年来在生物制药制造领域所见的最令人振奋的进展。Deniz 及其团队构建了长期以来在活细胞药物生产中缺失的控制系统。我期待 NantWorks、其关联公司与 Prolific 在多个领域展开合作，”NantWorks 创始人 Patrick Soon-Shiong 博士表示。

'Prolific's optogenetic platform brings precise, programmable control to cells, with major potential across biopharma and beyond. Its early traction already shows strong commercial promise,' commented James Stewart, General Partner of Atoms & Bits.

“Prolific的光遗传学平台为细胞带来了精确且可编程的控制能力，在生物制药及其他领域具有巨大的应用潜力。其早期市场反响已展现出强劲的商业前景。”Atoms & Bits普通合伙人詹姆斯·斯图尔特评论道。

About Prolific Machines

关于 Prolific Machines

Prolific is a biotechnology-driven company advancing biologics development and manufacturing through integrated optogenetics-enabled solutions delivering breakthrough yields, superior on-target quality, and precise process control. Its next-generation integrated platform combines light-inducible cell lines, plug-and-play illumination systems, and AI-driven process optimization to enable dynamic control of protein expression in standard bioreactors.

Prolific 是一家由生物技术驱动的公司，通过集成的光遗传学赋能解决方案，推动生物制剂的开发与生产，实现突破性的产量、卓越的靶向质量以及精确的过程控制。其下一代集成平台将光诱导细胞系、即插即用式照明系统和人工智能驱动的过程优化相结合，能够在标准生物反应器中实现对蛋白质表达的动态控制。

Prolific partners with biotech and pharmaceutical companies and CDMOs worldwide to advance programs from development toward scalable, cost-efficient manufacturing. To learn more, visit prolific-machines.com.

Prolific 与全球各地的生物技术公司、制药公司和合同研发生产组织（CDMO）合作，推动项目从开发阶段迈向可扩展且具成本效益的生产阶段。欲了解更多信息，请访问 prolific-machines.com。

About Atoms & Bits

关于原子与比特

Atoms & Bits is a growth-stage venture capital firm backing companies at the intersection of the digital and physical worlds. Founded by the teams behind Level One Fund and Primal Capital, the firm partners with founders leveraging advances in AI, software and computation to build transformative products and infrastructure in the physical world.

Atoms & Bits 是一家处于成长期的风险投资公司，专注于支持数字世界与物理世界交汇领域的企业。该公司由 Level One Fund 和 Primal Capital 背后的团队创立，与那些利用人工智能、软件和计算技术进步的创始人合作，在物理世界中打造具有变革性的产品和基础设施。

Learn more at .

了解更多，请访问。

https://atomsandbits.xyz

https://atomsandbits.xyz

.

。

About NantWorks

关于 NantWorks

NantWorks, LLC applies new innovative approaches and new technologies to solving global problems.  NantWorks is focusing on three pillars: health & life sciences; energy & renewables; and connectivity & communications.

NantWorks, LLC 运用新的创新方法和技术来解决全球性问题。NantWorks 专注于三大支柱领域：健康与生命科学；能源与可再生能源；以及连接与通信。

Founded by Dr. Patrick Soon-Shiong, scientist and inventor of the first human nanoparticle chemotherapeutic agent Abraxane, the core mission for NantWorks is convergence: to develop and deliver a diverse range of technologies that accelerate innovation, broaden the scope of scientific discovery, enhance ground-breaking research, and improve healthcare treatment for those in need..

NantWorks 由科学家、首款人类纳米颗粒化疗药物 Abraxane 的发明者 Patrick Soon-Shiong 博士创立，其核心使命是融合：开发并提供多样化的技术，以加速创新、拓展科学发现的范畴、增强突破性研究，并改善有需要人群的医疗保健治疗。

Media Contacts

媒体联系人

Miles Fisher-Pollard

迈尔斯·费舍尔-波拉德

Orientation Marketing

定向营销

[email protected]

[email protected]

SOURCE Prolific Machines

来源：Prolific Machines

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示